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ABSTRACT
Exosomes are extracellular vesicles with diameters ranging from 30 to 150 nm. 
They can be secreted by all cell types and transfer information in the form of their 
contents, which include proteins, lipids and nucleic acids, to other cells throughout 
the body. They have roles in normal physiological processes as well as in disease 
development. Here, we review recent findings regarding tumor-derived exosomes, 
including methods for their extraction and preservation. We also describe the actions 
of exosomes in tumorigenesis. The exosomal antigen-presenting effect during 
antitumor immune responses and its suppressive function in immune tolerance 
are discussed. Finally, we describe the potential application of exosomes to cancer 
therapy and liquid biopsy.
INTRODUCTION
All prokaryotic and eukaryotic cells secrete 
extracellular vesicles (EVs) in order to exchange 
information [1]. Johnstone et al. first described EV 
formation during reticulocyte maturation [2]. Currently, 
EVs are classified into at least three main subgroups 
including microvesicles, apoptotic bodies, and exosomes. 
Exosomes in particular have been shown to play important 
roles in cardiovascular disease [3], neurological disease 
[4], and pain sensation [5]. Yáñez-Mó et al. provided a 
comprehensive review of our current understanding of the 
biological properties and physiological roles of EVs [1]. 
The role of exosomes in cancer development is 
of particular interest to oncologists because cancer cells 
secrete at least 10-fold more exosomes than normal cells, 
and tumor-derived exosomes (TDEs) can facilitate cell-
cell communication through the transport of growth 
factors, chemokines, microRNAs, and other small 
molecules. Exosomes are protected by a lipid bilayer, 
which enables them to carry genetic information (e.g. 
miRNAs) to distant sites through the bloodstream. They 
may induce metastatic niche formation in target organs, 
which facilitates cancer cell colonization. Here, we first 
review the basic methodology for exosome extraction 
and preservation. Next, we discuss the exosomal antigen-
presenting effect in the antitumor immune response and 
its suppressive function in immune tolerance. Finally, we 
describe potential applications for exosomes in cancer 
therapy and liquid biopsy.
PREPARATION, IDENTIFICATION, AND 
PRESERVATION OF TUMOR-DERIVED 
EXOSOMES
Initially, differential centrifugation was used 
to purify reticulocyte exosomes from tissue culture 
medium [2]. Taylor et al. first isolated circulating 
TDEs using modified magnetic-activated cell sorting 
protocol with anti-EpCAM in order to identify miRNA 
signatures in TDEs that could be used as diagnostic 
biomarkers in ovarian cancer [6]. The gold standard of 
exosome preparation is sucrose gradient enrichment 
after ultracentrifugation (UC). Thery et al. developed a 
protocol for the isolation and characterization of exosomes 
from both cell culture medium and biological fluids [7, 
8]. However, Abramowicz et al. determined that UC 
combined with iodixanol density gradient centrifugation 
or gel filtration yielded higher quality exosomes. 
Importantly, this method was reliable and suitable for 
mass spectrometry [9]. Commercial exosome extraction 
kits also exist. Interestingly, Deun et al. performed a 
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comparative analysis of UC, ultrafiltration, and several of 
these kits. The results indicated centrifuge-based methods 
for exosome concentration were optimal. Although 
commercial precipitation protocols could generate higher 
yields of concentrated exosomes, they provided the least 
pure preparations [10]. A summary of the advantages and 
disadvantages of the different extraction techniques is 
shown in Table 1. 
Recently, a new method for exosome purification 
was developed based on the precipitation of EVs 
with polyethylene glycol. This was referred to as the 
“ExtraPEG” method [11]. This protocol is interesting 
because it is faster than ultrafiltration and costs less than 
commercial kits. We have obtained similar results in our 
lab, but still use the ultrafiltration and sucrose gradient 
method as the last step of our preparation to achieve a 
more pure population of exosomes. Weng et al. used a 
similar approach to isolate exosomes from cell culture 
supernatants for protein identification [12]. Overall, we 
believe that the most effective method is UC combined 
with density gradient centrifugation. Paolini et al. showed 
that UC alone had less of an ability to induce NF-κB 
nuclear translocation in endothelial cells, underscoring 
the need for density gradient centrifugation in addition to 
UC [13].
There are several alternative methods to extract 
exosomes if the original source is difficult to obtain. For 
example, exosomes can be isolated from various body 
fluids including serum, urine and cerebrospinal fluid [19-
24]. Yoshioka et al. developed a rapid and accurate liquid 
biopsy technique called Exoscreen to identify and quantify 
exosomes in blood samples [25]. In addition, Musante 
et al. developed a hydrostatic dialysis method for the 
isolation of exosomes from urine samples. The Musante 
method is highly cost-effective and maximizes the benefits 
of biobanking [26]. 
Following exosome isolation, the next step 
is to ensure the purity of the preparation. This step 
requires morphological analysis. Exosomes typically 
have diameters of 30-150 nm. Transmission electron 
microscopy is therefore essential to obtain high-resolution 
images of exosomes. We recommend labeling exosomal 
membrane proteins such as CD9 prior to imaging [8]. 
Additional exosomal markers can be found here: http://
exocarta.org/exosome_markers_new. Negative controls 
are also recommended by the International Society for 
Extracellular Vesicles. These include Grp94 (HSP90B1) 
and calnexin (CANX), which are both markers of the 
endoplasmic reticulum, GM130 (a Golgi marker), 
cytochrome C (a mitochondrial marker), histones (nuclear 
markers), and Argonaute (AGO), which marks the RISC 
complex [27]. Fluorescence active cell sorting (FACS) 
and enzyme-linked immunosorbent assays (ELISA) are 
advantageous for high-throughput analysis. However, 
because other antigens can interfere with the assays, 
ELISA is not ideal for exosome detection. FACS analysis 
Table 1: Standard methods for exosome extraction 
Extraction 
principle Affinity precipitation
Size exclusion Membrane affinity 
filtration
Ultracentrifugation (UC)
+
Density gradient 
centrifugation
Representative 
commercial
kits
Invitrogen™ 
[14]
SBI™
ExoQuick-TC
[15]
101Bio™
P100
[16]
iZON™
qEV
[17]
QIAGEN™
exoEasy
[18]
/
Cell
media 
required
5–10 mL
Up to 500 µL Up to 500 µL Up to 36 mL
25–125 mL, depending on cell 
type
Time Mix well overnight +1 hour 2 days Approximately 30 min 12–24 hours
Advantage
(Based on our 
concept)
Widely and easily used; high yield Less time and less impure protein Reliable
Disadvantage
(Based on our 
concept)
Impure protein
Valuable
Contains few 
large vesicles
Valuable
Selects for 
a specific 
subgroup
Recourse large
Time cost Instrument required
Purity* + to ++ ++ to +++ UC: +++UC + DGC: ++++++
Cost (one-
time) $10 $20 $30 $40 $40 Ultracentrifuge daily use
*Legend: +, very low; ++, low; +++, moderate; ++++, high; +++++, very high.
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involves an advanced device designed for very small 
particles, but it has additional associated costs. Further, 
it can be difficult to detect the exact number of exosomes 
and estimate the concentration. Normally, direct cleavage 
of exosome surface proteins can be used to estimate the 
total protein concentration, but it is ideal to obtain a more 
precise number of exosomes. Therefore, Nanoparticle 
Tracking Analysis and qNano are typically used in 
these applications. There has also been progress in the 
development of microfluidics [28-31].
New insights regarding exosome preservation are 
emerging. Previous reports have indicated that exosomal 
size decreases by approximately 60% after storage at 
37°C for 2 days. However, the original size is preserved 
when exosomes are stored at -80°C for 2 days. It is also 
possible to preserve exosomes in either culture medium 
or phosphate-buffered saline at -80°C for longer periods 
of time [32, 33]. However, exosomes isolated using the 
ExoQuick kit are only stable for up to 18 h, even if they are 
stored at -80°C [3]. Exosomes extracted by ultrafiltration 
or UC will begin to degrade and release their contents 
after 2 h of storage at 37°C [34]. Because the proteins and 
nucleic acids in exosomes are relatively unstable, storage 
at -80°C is recommended. 
THE ROLES OF EXOSOMES IN THE 
METASTASIS OF SOLID TUMORS
Cell-cell communication can occur through various 
signaling molecules including chemical and electrical. 
Valadi et al. proposed that communication could also be 
mediated by exosomal RNA (mRNAs and microRNAs) 
[35]. Interestingly, amplification of oncogenes was 
observed in EVs [36]. More recently, mitochondrial 
DNA (mtDNA) was detected in exosomes [37]. Finally, 
retrotransposon RNA transcripts and single-stranded DNA 
were detected in exosomes [38]. Detailed analyses of the 
nucleic acid content of TDEs has revealed the presence 
of both double-stranded DNA [39] and circular RNA 
[40]. It is important to note that mRNA mutants/variants 
and miRNAs have been detected in serum microvesicles 
[36]. Exosomal DNA was representative of the entire 
genome and the mutational status of the corresponding 
parental tumor cell [38, 39]. Recently, exosome transfer 
from cancer cells to other cell types was observed in vivo. 
Using a Cre-LoxP-based approach, Zomer et al. observed 
uptake of EVs by tumor cells. Following uptake of EVs by 
more malignant cells, less malignant tumor cells displayed 
enhanced migratory behavior and metastatic capacity 
[41]. Malignant cells have the ability to transfer genetic 
information to other cells in the tumor microenvironment 
through exosomes. Examples of microRNA transport 
between cancer cells and tumor-associated cells through 
exosomes are shown in Table 2. Collectively, the data 
indicate that exosomal miRNAs contribute to cancer cell 
proliferation, metastasis, dormancy, and drug resistance. 
The main functions of exosomes are described in 
Table 2. Here, we focus on the roles of exosomes in solid 
tumor metastasis. There are three general mechanisms by 
which cancer cells can communicate with other cells in 
the microenvironment. First, less invasive tumor cells can 
become more malignant by taking up microRNAs secreted 
by invasive tumor cells in exosomes. Melo et al. found that 
exosomes derived from either a malignant breast cancer 
cell line or serum from breast cancer patients instigated 
nontumorigenic epithelial cells to form tumors in mice via 
RISC-associated miRNAs. They observed an increase in 
cell proliferation and viability in non-malignant cells after 
treatment with exosomes derived from malignant cells 
[42]. Singh et al. found that metastatic MDA-MB-231 
breast cancer cells had high expression of miR-10b and 
actively secreted exosomes containing this miRNA into 
the culture medium, which was not observed in cultures 
of non-metastatic or non-malignant cells. Exosomal miR-
10b suppressed the protein level of target genes such as 
HOXD10 and KLF4. Treatment with exosomes derived 
from MDA-MB-231 cells promoted invasion of non-
malignant cells [43]. RNA sequencing confirmed that 
exosomes contained more miRNAs than expected [38, 44, 
45] and indicated that they were not sorted into exosomes 
randomly [46, 47]. Therefore, it is not surprising that 
malignant cells could alter the behavior of less malignant 
or non-malignant cells. 
The second mechanism by which cancer 
cells can communicate with other cells in the tumor 
microenvironment is through exosomes. Zhou et al. 
determined that exosomes derived from metastatic breast 
cancer cells destroyed vascular endothelial barriers to 
promote metastasis through miR-105, which targets the 
tight junction protein ZO-1. Overexpression of miR-105 
in non-metastatic cancer cells promoted metastasis and 
vascular permeability in distant organs following the 
destruction of tight junctions, which are natural barriers 
to metastasis [48]. The mechanisms by which exosomes 
function in pre-metastatic niche formation are of particular 
interest. Exosomes derived from tumor cells could be 
transported to specific organs [49]. It is possible that 
exosomes, which are representative of primary cancer 
cells, could perform similar functions in pre-metastatic 
niches to those performed by cancer cells at the primary 
tumor site (e.g. instigating endothelial cells and various 
types of macrophagocytes). Lyden et al. used the word 
“educating” to describe how exosomes alter the behavior 
of normal cells. They found that exosomes from highly 
metastatic melanomas enhanced the metastatic behavior 
of primary tumor cells through “educating” bone marrow 
progenitors [50]. They also determined that exosomes 
derived from pancreatic ductal adenocarcinomas were 
more frequently observed in the liver than in the lung. 
Exosomes containing macrophage migration inhibitory 
factor recruited macrophages from the bone marrow to the 
liver to help initiate pre-metastatic niche formation [51]. 
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Table 2: Intercellular communication through exosome-derived microRNAs in different cancer models.
Tumor Donor Contents Recipient Target(s) Function(s) Classification Ref.
Breast 
cancer
MDA-MB-231 miR-105 Endothelial cells Protein ZO-1 Destroys tight junctions and the integrity of natural barriers to metastasis. Metastasis [48]
MDA-MB-231 miR-10b HMLE (MCF-7) HOXD10/KLF4 Induces invasion of non-malignant HMLE cells. Metastasis [43]
MDA-MB-231
4T1 miR-210 Endothelial cells /
Suppresses expression of specific target genes resulting in 
enhanced angiogenesis. Metastasis [66]
Endothelial cells miR-503 Breast cancer cells CCND2/ CCND Alters proliferation and invasion. Metastasis [67]
EGCG-treated 4T1 
cells miR-16 Macrophages / Inhibits TAM infiltration and M2 polarization. Metastasis [68]
Mesenchymal
stem cells miR-16 4T1 VEGF mRNA
Down-regulates the expression of vascular endothelial 
growth factor (VEGF) in tumor cells. Metastasis [69]
Tumor Donor Contents Recipient Target(s) Function(s) Classification Ref.
Breast 
cancer
Pre-adipocyte
(3T3L1) miR-140 MCF10 SOX9 Regulates differentiation, stemness, and migration. Metastasis [70]
Breast 
cancer patients/
MCF10A
miR-122
Recipient pre-
metastatic niche 
cells
PKM2 and GLUT1 Suppresses glucose uptake by niche cells by down-regulating pyruvate kinase Proliferation [71]
Bone marrow
mesenchymal
stem cells
miR-23b Breast cancer cells MARCKS
Decreases MARCKS expression and promotes 
breast cancer cell dormancy in the metastatic niche. Dormancy [72]
Bone marrow
stroma
miR-127, -197, 
-222, and -223 MDA-MB-231 CXCL12
Reduce CXCL12 levels and decreases proliferation. 
Elicit dormancy in bone marrow metastases in 
breast cancer.
Dormancy [73]
Hs578T and 
Hs578Ts(i)8 miR-134
Breast cancer 
cells STAT5B
Reduces STAT5B and Hsp90 expression. Decreases 
cell migration and invasion. Drug resistance [74]
MCF-7 (Tamoxifen 
resistant)
miR-221/
-222
MCF-7 
(Tamoxifen- 
sensitive)
P27 and ERα Enhances tamoxifen resistance in recipient cells. Drug resistance [75]
IL-4-activated 
macrophages miR-223 MDA-MB-231
Mef2c-
β-catenin Promotes the invasion of breast cancer cells. Metastasis [76]
Mesenchymal stem 
cells miR-124/ -145
Glioma cells and 
glioma stem cells SCP-1/Sox2
Decrease the migration of glioma cells and the self-
renewal of glioma stem cells. Proliferation [77]
Bone marrow-
derived MSCs
miR-21/
-3a
Breast cancer 
cells
TPM1/PDCD4/
Bcl-2 Elicit pro-tumorigenic and anti-apoptotic effects. Proliferation [78]
Lung cancer
Immune cells miR-155/-146a Immune cells
HO1/ IRAK1 and 
TRAF6
MiR-155 enhances while miR-146a reduces 
inflammatory gene expression. Promotes endotoxin-
induced inflammation.
Inflammation [79]
Mast cell / A549 KIT-SCF/ PI3K Enhances proliferation in recipient tumor cells. Proliferation [80]
Tumor Donor Contents Recipient Target(s) Function(s) Classification Ref.
Lung 
cancer
A549 miR-192 Endothelial cells ICAM-1/ PTPRJ
Regulates non-cell-autonomous invasiveness, and tumor-
induced osteoclastogenesis. Bone metastasis [81]
Bronchial epithelial 
(HBE) cells miR-21 Normal HBE cells STAT3
Increases VEGF levels in recipient cells, which is involved 
in angiogenesis and malignant transformation of HBE cells. Angiogenesis [82]
Lung adenocarcinoma miR-210 Stromal cells Ephrin A3 Promotes angiogenesis. Angiogenesis [83]
Lung cancer A-549 and 
SK-MES cells
miR-21/
-29a Immune cells
Toll-like
receptors 7 
(TLR7) and 8 
(TLR8)
Promote NF-kB activation and the secretion of pro-metastatic 
inflammatory cytokines. Pre-metastasis [84]
A549 miR-192 Endothelial cells ICAM-1/ PTPRJ
Regulates non-cell-autonomous invasiveness, and tumor-
induced osteoclastogenesis. Bone metastasis [81]
Bronchial epithelial 
(HBE) cells miR-21 Normal HBE cells STAT3
Increases VEGF levels in recipient cells, which is involved 
in angiogenesis and malignant transformation of HBE cells. Angiogenesis [82]
adenocarcinoma miR-210 Stromal cells Ephrin A3 Promotes angiogenesis. Angiogenesis [83]
Lung cancer A-549 and 
SK-MES cells
miR-21/
-29a Immune cells
Toll-like
receptors 7/8
Promote NF-kB activation and the secretion of pro-metastatic 
inflammatory cytokines. Metastasis [84]
Tumor Donor Contents Recipient Target(s) Function(s) Classification Ref.
Prostate 
cancer
Docetaxel-resistant 
prostate cancer cells miR-34a Docetaxel-resistant
B-cell
Lymphoma 2
Influences cell response to docetaxel in prostate 
cancer cells through regulation of anti-apoptotic 
BCL-2.
Drug resistance [85]
DIAPH3-silenced cells miR-125a macrophages AKT1 Suppresses AKT1 expression and proliferation of cancer. Proliferation [86]
Bladder 
cancer
Exosome-derived miR-
29c miR-29c BIU-87 cells
BCL-2 and 
MCL-1
Exosome-derived microRNA29c induces 
apoptosis in bladder cancer cells by down-
regulating BCL-2 and MCL-1.
Apoptosis [87]
Melanoma
A375 and SK-MEL-28 miR-31, -185, and -34b Normal melanocytes
HAPLN1, 
GRP78 / Metastasis [88]
Metastatic melanoma cell 
lines miR-222
Primary melanoma 
cell lines p27Kip1 Activates the PI3K/AKT pathway. Metastasis [89]
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An analogous mechanism was discovered in 
pancreatic cancer. Exosomes from pancreatic ductal 
adenocarcinomas fused with resident cells at the metastatic 
location, which included liver Kupffer cells and lung 
epithelial cells. In addition, exosome integrin uptake by 
resident cells activated Src and altered the expression of 
pro-migratory and pro-inflammatory S100 genes, which 
are associated with metastasis [52]. Grange et al. reported 
that in human renal cell carcinoma, microvesicles released 
by CD105 positive tumor-initiating cells promoted 
angiogenesis and enhanced lung metastasis [53]. All of 
the work we have described is based on in vitro studies of 
purified TDEs. Whether TDEs perform these functions in 
vivo is still not clear [54]. Our data indicate that colorectal 
cancer-derived exosomes could be used to predict organ-
specific metastasis (unpublished data). 
A third mode of communication involves exosomes 
derived from normal cells, which can alter the behavior 
of tumor cells. Zhang et al. revealed that both human and 
mouse tumor cells lost PTEN expression after metastasis 
to the brain, but not to other organs. They determined that 
PTEN expression was regulated by microRNAs from 
brain astrocytes [55]. These results indicate that organ-
specific metastasis is not only determined by TDEs, but 
Colorectal 
cancer
HCT-15, SW480 and 
WiDr
miR-21, -192 
and -221 HepG2 and A549 /
Regulate the expression of target genes in 
HepG2 and A549 cells. May promote various 
functions.
/ [90]
Gastric 
cancer
Macrophage miR-21 BGC-823 PDCD4 MiR-21 inhibitor-loaded exosomes promote migration and reduce apoptosis. Metastasis [91]
Mesenchymal stem cells miR-221 HGC-27 / Promotes HGC-27 growth and migration. Metastasis [92]
Tumor Donor Contents Recipient Target(s) Function(s) Classification Ref.
Gastric cancer
AZ-P7a Let-7 AZ-521 RAS and HMGA2 Induces tumorigenesis and metastasis. Metastasis [93]
OCUM-2MD3 miR-21 and -1225-5p OCUM-2M /
MiR-21 and miR-1225-5p may prepare a pre-
metastatic niche in the peritoneum for the 
dissemination and colonization of metastatic 
cancer cells.
Metastasis [94]
Liver cancer
Macrophages miR-142 and -223
Hepatocellular 
carcinoma cells 
(HuH7 and HepG2)
Stathmin-1/
IGF1R Inhibits proliferation of cancer cells. Inhibitor [95]
Huh7 cells miR-122 HepG2 cells IGF1R mRNA Reduced growth and proliferation of recipient HepG2 cells. Inhibitor [96]
Hep3B, HepG2, 
and PLC/PRF/5 miR-584
Hep3B, HepG2 and 
PLC/PRF/5
TGF-β 
activated 
kinase-1 
(TAK1)
HCC cell-derived exosomes modulate TAK1 
expression and associated signaling. They also 
enhance the growth of transformed recipient cells.
Proliferation [97]
Cholangiocarcinoma KMBC and HuCCT1 /
Mesenchymal stem 
cells /
Enhance MSC migratory capability and 
expression of alpha-smooth muscle actin mRNA. 
Promote the release of CXCL-1, CCL2, and IL-6.
Metastasis [98]
Tumor Donor Contents Recipient Target(s) Function(s) Classification Ref.
Hematological 
malignancies
K562 under 
hypoxic 
conditions
miR-210 Umbilical vein endothelial cells EFNA3
Exosomal miRNAs derived from cancer cells 
under hypoxic conditions may affect angiogenic 
activity in endothelial cells.
Metastasis [99]
LAMA84 miR-126 Endothelial cells CXCL12 and VCAM1
HUVECs with a miR-126 inhibitor reversed 
the decrease in CXCL12, restores motility and 
adhesion in LAMA84 cells.
Metastasis [100]
Chronic 
lymphocytic 
leukemia 
(MEC1)
miR-202-3p Human stromal cells c-Fos and ATM Enhances proliferation of recipient cells. Proliferation [101]
K562 cells miR-92a Umbilical vein endothelial cells Integrin α5
Enhances endothelial cell migration and tube 
formation. Metastasis [102]
CLL cells miR-21 MSCs and endothelial cells /
Induce differentiation of stromal cells into cancer-
associated fibroblasts. Metastasis [103]
Multiple 
myeloma cells miR-135b endothelial cells FIH-1
Exosomal miR-135b from HR-MM cells 
enhances endothelial tube formation under 
hypoxic conditions via the HIF-FIH signaling 
pathway.
Metastasis [104]
Neuroblastoma
NBL cells miR-21 Human monocytes TLR8-NF-кB
/ Drug resistance [105]
Monocytes miR-155 NBL cells TERF1
Tumor Donor Contents Recipient Target(s) Function(s) Classification Ref.
Ovarian 
cancer
SKOV-3 let-7 family OVCAR-3 /
Exosome release varies between ovarian cancer cell 
lines and is correlated with invasive potential.
Metastasis [106]
CP70 miR-21-5p A2780 NAV3 Increases platinum-resistance in A2780 cells. Drug resistance [107]
High-grade ovarian cancer
ATF2, MTA1, 
and ROCK1/2
Endothelial 
cells /
Exosomes derived from high-grade ovarian cancer 
alter angiogenesis compared to non-high-grade 
ovarian cancer cells.
Metastasis [108]
The serum of patients with 
NPC or TW03 cells
miR-24-3p, 
-891a, and -106a-
5p
T-cell MARK1 Alter T-cell proliferation and differentiation. Metastasis [109]
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also by specific organ-associated cells. In Table 2 we 
have concluded other models of this kind of transferring. 
Interestingly, TDEs can fuse with non-parenchymal cells 
in various organs, leading to inflammation, anoxia, and 
vascularization in the metastatic microenvironment. 
Collectively, the data indicate that exosomes play 
important roles in pre-metastatic niche formation. 
Quantitative proteomic analysis of EVs has resulted 
in the identification of proteins in exosomal membranes 
and lumens, which may contribute to metastasis [56-
59]. Public databases including Vesiclepedia (www.
microvesicles.org) [60], EVpedia (www.evpedia.info) [61, 
62], and ExoCarta (www.exocarta.org) [63] can be used to 
identify exosomal proteins. For example, Timothy et al. 
searched all of the proteins in the Vesiclepedia database 
and used a gene ontology approach to identify regulatory 
factors involved in cancer initiation and progression [64]. 
Additionally, Ostenfeld et al. determined that exosomes 
derived from a metastatic human bladder carcinoma 
cell line had high expression of vimentin and hepatoma-
derived growth factor in the membrane, and casein kinase 
II and annexin A2 in the lumen using quantitative isobaric 
tags for relative and absolute quantitative proteomics 
[57]. Finally, Lee et al. performed a proteomic analysis to 
identify differences in protein expression between MCF-7 
and MDA-MB-231 cells, and described a new function 
for EDIL3 on EVs, which enhanced cell invasion and lung 
metastasis in vivo [65].
THE ROLES OF TUMOR-DERIVED 
EXOSOMES IN THE ANTI-TUMOR 
IMMUNE RESPONSE
Exosomal antigen presentation in the antitumor 
immune response 
TDEs contain tumor-associated antigens (TAAs) 
and major histocompatibility complex (MHC) class I 
molecules [110, 111]. Exosomes deliver TAAs to dendritic 
cells (DCs), which results in the induction of antigen-
specific CD8 T-cells and tumor rejection in various 
prophylaxis and therapeutic murine tumor xenograft 
models. Importantly, coupling of TAAs to exosomes 
elicited a more efficient antitumor immune response and 
had a stronger therapeutic effect compared to subcutaneous 
delivery of TAAs in a mouse fibrosarcoma model 
[112]. DCs loaded with syngeneic or allogeneic TDEs 
stimulated regression of pre-established tumors in mice 
[110, 111]. Another approach to exosome-based cancer 
immunotherapy involves the applications of DCs pulsed 
with tumor peptides [113-116]. Both mouse and human 
TAA-loaded DCs can secrete exosomes that express 
functional MHC class I, II, and T-cell co-stimulatory 
molecules. These exosomes have been reported to 
stimulate tumor-specific CD8 T-cells in vivo and inhibit 
the growth of transplanted tumors in mice. Clinical grade 
exosomes were first isolated from DCs and characterized. 
They were then evaluated in clinical trials for various 
cancers [116-118]. In a phase I clinical trial, exosomes 
derived from autologous DCs loaded with MAGE 3 
peptides were investigated in stage III/IV melanoma 
patients [117]. This was the first trial to demonstrate the 
feasibility of large-scale exosome production and safety 
of exosome administration. Several other phase I or phase 
II clinical trials involving exosome-based regimens have 
been initiated in patients with non-small cell lung cancer, 
malignant glioma, breast cancer, and gastric cancer [118]. 
The immunosuppressive effects of tumor-derived 
exosomes
TDEs are a major source of tumor antigens. 
However, recent studies have shown that TDEs can also 
suppress antigen-specific or non-specific anti-tumor 
responses. For example, TDEs are rich in FasL, TRAIL, 
and galectin-9, which stimulate T-cell apoptosis [119-121]. 
Moreover, TDEs suppress CD3-ζ chain expression in 
T-cells, which prevents activation [122]. They also inhibit 
NKG2D-dependent cytotoxicity in natural killer cells and 
CD8 T-cells [123].
In addition to the effects of TDEs on T-cells and 
natural killer cells, TDEs also modulate antigen-presenting 
cells, which controls differentiation. For example, they 
can induce monocyte differentiation into myeloid-derived 
suppressor cells (MDSCs), which inhibit the antitumor 
immune response [123]. The prostaglandin E2, TGF-β, 
Hsp70, and miRNAs contained in tumor-derived vesicles 
play important roles in monocyte differentiation [124-
126]. Moreover, in tumor-bearing mice, blood-borne 
exosomes positive for CD11b could suppress tumor Ag-
specific responses through a MHC Class-II dependent 
and MHC Class-I independent mechanism [127]. These 
observations suggest that TDEs initially stimulate 
CD11-positive antigen presenting cells in the tumor 
microenvironment, which then secrete immunosuppressive 
MHC Class-II, CD11b-positive vesicles into the 
circulation. Exosomes released by human melanoma and 
colorectal carcinoma cells impair differentiation of blood 
CD14+ monocytes into immune-stimulating DCs and 
replace them with highly immunosuppressive MDSCs that 
inhibit T-cell functions through secretion of TGF-b [123, 
128]. Thus, the MDSC generation, expansion, migration, 
and activation are controlled by various mediators of 
chronic inflammation [129-132]. 
Intriguingly, all of these factors have been observed 
in the tumor microenvironment in a soluble form. 
However, recent studies have indicated that they can be 
transported to distant locations by TDEs, which alters 
the differentiation and function of myeloid cells in the 
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favor of immunosuppressive MDSCs at metastatic sites 
[129, 130, 133]. MDSCs then induce or support the 
functions of regulatory T-cells (Tregs), which have key 
roles in the tumor-suppressive microenvironment. In 
addition, TDEs can enhance Treg function and inhibit 
apoptosis. For example, the expression of membrane-
bound TGF-b and other cytokines, growth factors, and 
matrix metalloproteinases from MDSCs are capable of 
directing CD4+ T-cells towards the Th2 and Treg lineages 
[134-137]. Finally, exosomes have been shown to convert 
conventional CD4+FoxP3- T-cells into highly suppressive 
and apoptosis-resistant Tregs via TGF-b and IL-10, and to 
promote Treg expansion [138, 139].
TUMOR-DERIVED EXOSOMES IN 
CLINICAL PRACTICE
The concentrations of exosomes cancer patient 
blood
The levels of exosomes in blood have been 
correlated with tumor development. Logozzi et al. 
observed an increase in CD63+ exosomes in melanoma 
patients compared to healthy donors [140]. In a study of 
lung adenocarcinoma, both the mean exosome and miRNA 
concentrations were higher in the lung adenocarcinoma 
compared to the control group [141]. The expression 
levels of exosomal miR-21 were correlated with advanced 
tumor stage, positive lymph node status, and metastasis 
in patients with esophageal squamous cell cancer [142]. 
In oral cancer, Ren et al. suggested that elevated levels 
of circulating microparticles were closely correlated with 
oral squamous cell carcinoma [143]. Using nanoparticle 
tracking analysis, Ayelet et al. determined that the 
concentration of exosomes in blood samples from oral 
cancer patients was higher than in healthy individuals. 
Additionally, they observed differences in the size 
distributions of the exosomes and marker expression 
between the two groups [144]. It is possible that surgery 
or treatment with cancer therapeutics could decrease the 
number of exosomes in blood. Indeed, exosomal miRNAs 
(a panel) decreased in the blood of patients with lung 
squamous cell carcinoma surgery [145]. Thus, exosome 
concentrations in blood may help physicians evaluate the 
results of surgery and detect relapse in cancer patients.
Applications of exosomes in cancer diagnosis 
and as prognostic markers in patients with solid 
tumors
Blood-based tumor markers such as cancer antigen 
199 and alpha-fetal protein are widely used in cancer 
diagnosis. Recently, Melo et al. demonstrated a high 
degree of specificity in detecting early pancreatic cancer 
through the use of glypican-1 circulating exosomes as 
markers [146]. This is just one advantage of exosomes 
in detecting early-stage cancers. TDEs can reach cells in 
distant organs and drive genetic alterations [36, 93, 147, 
148]. Eichelser et al. observed an increase in circulating 
exosomal miRNA-373 in receptor-negative breast cancer 
patients [149]. Additionally, Huang et al. determined 
that miR-1290 and miR-375 were prognostic markers 
in castration-resistant prostate cancer [150]. Finally, 
Matsumura et al. found that the exosomal miR-19a cluster 
expression level in serum was correlated with recurrence 
in colorectal cancer [151]. The results of a meta-analysis 
suggested that plasma miR-21 may be a reliable and non-
invasive biomarker for colorectal cancer diagnosis [152]. 
In addition to circulating exosomes, three fecal microRNA 
levels were significantly higher in colorectal cancer 
patients [153]. 
New technology has been developed to capture 
circulating exosomes [28], which can serve as tumor 
markers for personalized diagnostics. The use of exosomes 
in liquid biopsy is also currently under investigation [154]. 
However, as Thery et al. noted, the testing will be more 
reliable and less complex if the contributions of exosomes 
and exosomal miRNA to cancer progression are elucidated 
[155]. In addition, circulating tumor cells contribute to 
cancer metastasis [156]. Therefore, a combination of 
exosomes and circulating tumor cell detection could 
improve the precision of cancer diagnosis. 
Circulating miRNAs can be (1) passively 
transported out of cells, (2) actively secreted by membrane 
vesicles, or (3) actively secreted by complex formation 
with lipoproteins (e.g. high-density lipoprotein) and RNA-
binding proteins (e.g. AGO2 and nucleophosmin 1) [157]. 
Arroyo et al. hypothesized that circulating miRNAs may 
not be not restricted to vesicles. Instead, most miRNAs 
are associated with circulating Ago2 complexes. Less 
than 10% of miRNAs are vesicle-associated, whereas 
it is possible that 90% of miRNAs in the circulation 
are present in a non-membrane bound form (e.g. in a 
ribonucleoprotein complex) [158]. However, Gallo et al. 
found that the majority of miRNAs that were detectable 
in serum and saliva were concentrated in exosomes. 
The differences in results could be explained by lysis of 
exosomes during the isolation process [159]. 
Given the large number of blood cells in circulation, 
most miRNAs likely exist in non-membrane bound forms. 
However, there is increasing evidence for the roles of 
TDEs in the release of intercellular signaling molecules. 
Considering exosomes typically target specific cells, 
compare with total circulating RNAs, it may be reasonable 
to detect exosomal miRNAs in clinical examinations. On 
the other hand, increases in the levels of specific miRNAs 
in the circulation may be readily detected in exosomes. 
This may assist physicians with predicting cancer patient 
prognosis. Although non-membrane-bound miRNAs are 
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stable in the blood, they are still regarded as non-specific 
by-products of cell activity and death. In addition, the 
biological functions of miRNAs have not been fully 
elucidated [160, 161]. Overall, exosomes and exosomal 
miRNAs in blood may be useful markers of early-stage 
cancer and may be predictive of prognosis.
Drug delivery
Exosomes can also be used for drug delivery. The 
development of nanoformulations has improved the 
therapeutic efficacy of drugs. Unfortunately, none of the 
nanotechniques avoid toxicity, and the drugs are typically 
cleared by the immune system immediately [162]. 
Exosomes are advantageous in that they can function as 
both synthetic nanocarriers and as cell-mediated drug 
delivery vehicles [163]. It is generally difficult to deliver 
drugs into the brain because of the selectivity of the blood-
brain barrier. However, exosomes are lipid soluble and 
can easily cross the blood-brain barrier [164]. There are 
at least three ways that drugs can be loaded into exosomes 
for delivery: 1) naïve exosomes isolated from parental 
cells can be loaded ex vivo, 2) parental cells can be loaded 
with a drug, which is then released in exosomes, or 3) 
parental cells can be infected/transfected with DNA that 
encodes therapeutically active compounds, which are then 
released in exosomes [163]. Batrakova et al. first delivered 
the enzyme catalase (a large therapeutic protein) to the 
brain by loading exosomes extracted from immune cells 
with the enzyme [165]. Importantly, exosomes have the 
natural ability to home to tumors without eliciting an 
immune response. Exosome-encapsulated paclitaxel is 
50 times more potent against drug-resistant lung cancer 
tumors [166].
CONCLUSIONS
There is compelling evidence for the roles of 
exosomes in cancer. Exosomes are distinct from other 
EVs. To date, most studies have analyzed mixed EV 
populations, and not all EV subgroups have been 
characterized. The formation of exosomes is tightly 
regulated to ensure content stability and maintain 
biological activity. Like seeds from soil (primary tumor), 
exosomes may serve as “Trojan Horses”. There are 
thousands of miRNAs with potential functions in cancer. 
However, significantly fewer are present in exosomes. 
The molecular mechanisms underlying the sorting and 
release of cellular contents into exosomes are not yet clear. 
Because exosomes comprise an information transduction 
pathway in cancer, they have the potential to educate and 
compel other cell types (e.g. immune cells) to build a niche 
suitable for CTC colonization. An increasing number of 
clinical tests have been performed to study exosomes, 
which contain specific miRNAs or surface proteins. It 
is important to note that TDEs are qualitatively different 
from those derived from non-cancerous cells. Additional 
studies are required to distinguish TDEs from exosomes 
secreted by normal cells. Finally, advances in technology 
will result in new insights into exosome function and 
therapeutic potential. 
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